Optima试验的最新结果即将在美国临床肿瘤学会年会上公布,这些数据为利用Prosigna基因检测指导早期乳腺癌患者化疗决策提供了新的有力证据。该研究进一步验证了基于肿瘤基因特征进行个体化治疗的有效性,有助于避免部分患者接受不必要的化疗。
Optima试验的最新结果即将在美国临床肿瘤学会年会上公布,这些数据为利用Prosigna基因检测指导早期乳腺癌患者化疗决策提供了新的有力证据。该研究进一步验证了基于肿瘤基因特征进行个体化治疗的有效性,有助于避免部分患者接受不必要的化疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.